glp-1 agonist therapy information platforms Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 Receptor Agonists as Treatments
Description
In order to speed up clinical studies and broaden therapeutic portfolios, the next-generation obesity drug pipeline market is also seeing an increase in partnerships between biotechnology companies and major pharmaceutical corporations
Ma T, Lu W, Wang Y, Qian P, Tian H, Gao X, et al
The microdosing approach to retatrutide has gained attention precisely because it minimizes side effects including heart rate changes
[DOI] [PubMed] [Google Scholar] 89.Schlogl H., Kabisch S., Horstmann A., Lohmann G., Muller K., Lepsien J
( )
